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Case report Clinical evidence for overcoming capecitabine 
resistance in a woman with breast cancer 
terminating in radiologically occult micronodular 
pseudo-cirrhosis with portal hypertension: a case 
report
Christa Fournier*1, Glenn Tisman1, Robert Kleinman2, Yong Park2 and William D MacDonald3
Abstract
Introduction: We report a case of stage IV breast cancer terminating in an unusual picture of radiologically occult 
micronodular pseudo-cirrhosis. Contrast-enhanced computed tomography showed no evidence of metastatic breast 
cancer within the liver. Unlike the few previously reported cases of intrasinusoidal spread of breast cancer, our patient 
was palliated with a transjugular intrahepatic portosystemic shunt along with salvage chemohormonal therapy. In 
addition, our patient demonstrated proof of the principle of the dependence of capecitabine (Xeloda) efficacy on dose 
scheduling as predicted by laboratory studies based on Gompertzian tumor growth and the Norton-Simon hypothesis.
Case presentation: We report the case of a 52-year-old Caucasian woman who developed radiological signs of portal 
hypertension without radiological evidence of hepatic metastasis five years after being diagnosed with metastatic 
breast cancer. She was receiving chemotherapy for stage IV breast cancer initially thought to be metastatic only to the 
bones. During salvage therapy with high-dose estradiol (Estradiol valerate), vinorelbine (Navelbine) and bevacizumab 
(Avastin), she suddenly developed signs of portal hypertension confirmed on computed tomography and by portal 
and systemic venous pressure measurements. Drug toxicity due to bevacizumab (Avastin) was initially and incorrectly 
entertained as a cause. The patient underwent palliative transjugular intrahepatic portosystemic shunt and 
transhepatic venous liver biopsy, which revealed the presence of rapidly progressive and uncontrolled metastatic 
breast cancer. The new discovery of radiologically occult intrasinusodal hepatic metastases with secondary 
micronodular cirrhosis was found to be the cause of her sudden onset portal hypertension. The patient's resistance to 
capecitabine (Xeloda) was reversed by changing the schedule of medication to biweekly 7/7 (7 days ingesting drug 
alternating with 7 days off drug) from the 14/7 (14 days ingesting drug alternating with a 7 day rest period) day 
schedule approved by the US Food and Drug Administration.
Conclusion: This case report demonstrates an unusual presentation of radiographically occult hepatic metastasis from 
breast cancer palliated with transjugular intrahepatic portosystemic shunt. All patients with advanced breast cancer 
developing unexpected portal hypertension should be considered candidates for liver biopsy despite normal 
computed tomography of the liver imaging results. This is the first report of a reversal of clinical resistance to 
capecitabine (Xeloda) by changing from the schedule of 14/7 day to a biweekly 7/7 day schedule. This suggests that a 
biweekly schedule may be best for some patients.Fournier et al. Journal of Medical Case Reports 2010, 4:112
http://www.jmedicalcasereports.com/content/4/1/112
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Introduction
We describe a patient who underwent extensive treat-
ment for stage IV breast cancer that had metastasized to
her bones and liver. She had unique and medically impor-
tant clinical features of radiologically occult liver metas-
tases and drug resistance to schedule-dependent
chemotherapy. Contrast-enhanced computed tomogra-
phy (CT) did not demonstrate metastatic liver disease,
although it did show advanced portal hypertension.
Three similar cases and a review of English literature by
Allison et al. confirmed the rarity of such a presentation
(21 reported cases) [1]. Most of the patients previously
reported were not treated with transjugular intrahepatic
portosystemic shunt (TIPS). Our patient underwent a
TIPS procedure, which rendered a modest relief of her
symptoms. Meanwhile, secondary hepatic encephalopa-
thy did not occur. It was apparent that our patient's drug
resistance to capecitabine (Xeloda) was reversed by
changing drug scheduling. Such had been previously pre-
dicted by laboratory experiments, thus lending support to
the validity of chemotherapy schedule modelling based
on Gompertzian tumor cell kinetics and the Norton-
Simon hypothesis [2-5].
Case presentation
A 52-year-old Caucasian woman was diagnosed at age 47
with Stage IIB, Grade II T2N3 Mx invasive ductal adeno-
carcinoma of the breast. She had 14 of 18 tumor positive
nodes, wherein one had capsular penetration. Examina-
tion showed the following values for our patient: estrogen
receptor = 69%, progesterone receptor = 27%, Ki67 = 10%
and HER2/neu was not over expressed. She then under-
went mastectomy. She was treated within one month
with adjuvant chemotherapy. For five months our patient
received dose-dense sequential hydroxydaunomycin
(Doxorubicin), paclitaxel (Taxol) and cyclophosphamide
(Cytoxan). She received four applications of each drug
once every 14 days.
After completing radiation therapy, she was started on
exemestane (Aromasin) and leuprolide (Lupron) for the
next nine months. On the eighth month, her CA 27 to 29
increased to 47 U/ml. Bone imaging confirmed osseous
metastases. At that time she elected not to receive intra-
venous chemotherapy. Her relapse after two years was
treated with metronomic low-dose oral cyclophosph-
amide (Cytoxan) and methotrexate (Trexall) plus tamox-
ifen (Soltamox). She showed no response to this
medication. She subsequently began monthly fulvestrant
(Faslodex) and weekly albumin-bound paclitaxel nano-
particles (Abraxane).
After a 5-month response, which was then followed by
resistance, these drugs were discontinued following a
total of 17 albumin-bound paclitaxel nanoparticles infu-
sions (Abraxane). She then complained of a new, diffuse
and severe bone pain. A bone scan confirmed that diffuse
bony metastases had progressed. This was associated
with a rise in her CEA from 37.2 to 75.1 ng/ml, CA 15-3
from 88 to 128 U/ml and CA 27-29 from140 U/ml to 285
U/ml. From 16 October 2006 to 15 April 2007, she was
treated with daily capecitabine (Xeloda) 1500 mg in the
morning and 1000 mg before bedtime two weeks on and
one week off as per the US Food and Drug Administra-
tion (FDA) approved 14/7 21-day cycle. This was her
maximally tolerated dose. She had severe diarrhea limited
by gastrointestinal toxicity when trying to increase the
dose of her medicaiton by an additional 500 mg/day. She
developed a 6-month tumor marker (CEA and CA 15-3)
and clinical response with complete relief of disabling dif-
fuse bone pain and tumor marker analysis as outlined in
Figure 1.
Subsequently, her tumor pain and markers increased
and 2 mg diethylstilbestrol compounded (DES) was
administered twice daily from 18 April 2007 to 17 June
2007. This treatment was judged to be ineffective.
She was rechallenged with capecitabine (Xeloda) and
the schedule was changed to the biweekly 7 days on, 7
days off regimen based on experiments by Dr. Larry Nor-
ton on the benefits of biweekly capecitabine (Xeloda) [5].
From 26 November 2007 to 03 June 2008, she took
capecitabine (Xeloda) 2000 mg orally twice daily one
week on and then followed by one week off. This dosing
schedule change was associated with a new durable clini-
cal and laboratory remission that lasted approximately six
months. Her CA 27-29 decreased from 1025 U/ml to 325
U/ml, while her CA 15-3 decreased from 325 U/ml (<35
U/ml) to 42 U/ml and her CEA from and 410 ng/ml (<5
ng/ml)) to 13.8 ng/ml. A summary of her tumor marker
response is presented in Figure 1.
Our patient's clinical response was characterized by
complete relief from diffuse bone pain which was similar
to her first capecitabine (Xeloda) response. However, on
18 June 2008, due to the recurrence of her intense bone
pain and increasing tumor markers (CEA from 13.8 to
220 ng/ml) she patient was withdrawn from capecitabine
(Xeloda) and given a single dose of ixabepilone (Ixempra).
She showed no response to this medicaiton. As a result,
bevacizumab (Avastin) was added every 14 days from 19
June 2008 to 10 September 2008 with a total of five doses.
On 14 August 2008, she began weekly vinorelbine (Navel-
bine). She was also started on weekly injections of 60 mg
estradiol velestrate on 21 August 2008.
During the month of October 2008, our patient com-
plained of abdominal fullness and pressure discomfort of
her upper abdomen. She had no history of hepatitis, cir-
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rhosis, illicit drug or excessive alcohol ingestion, although
she had nausea and loss of appetite. Blood studies
revealed the following values: SGOT = 166 (<42), SGPT =
232 (<40), GGT = 161(<24), total bilirubin = 0.8 (<1.2),
white blood cell = 8320, hematocrit = 24.7%, mean cor-
puscular volume = 86.6 and platelets = 50,000/mm3. A
metastatic evaluation including bone X-rays, contrast
enhanced CT of the chest, abdomen and pelvis, as well as
CT angiogram of her lungs was completed. The studies
revealed no evidence for hepatic metastases, an absence
of pulmonary emboli, and the presence of diffuse osteo-
blastic bone metastases. There was unexpected ascites,
splenomegaly and esophageal varacies suggestive of por-
tal hypertension (Figures 2 and 3). Because of the pro-
gressive ascites, splenomegaly, abdominal discomfort and
nausea, along with presumed hypersplenic sequestration
of platelets, which limited chemotherapy options, our
patient underwent a TIPS procedure with concomitant
diagnostic transhepatic venous liver biopsy.
A portal venogram confirmed the presence of esopha-
geal varacies in our patient. Pre-TIPS portal venous pres-
sure measured 31 mmHg, while her central venous
pressure was at 8 mmHg. Her portal systemic gradient
was 23 mmHg (normal<10). Post-TIPS the portal-sys-
temic gradient decreased to normal = 3 mmHg. This was
associated with a rapid shift of ascitic fluid into the sys-
temic circulation with transient pulmonary edema and
dyspnea on the day of the procedure. Encephalopathy did
not occur. After a rapid and almost complete resolution
of her ascitic accumulation our patient was significantly
relieved of her abdominal discomfort. Her platelet count
only slightly increased from 50 to 70,000 a week after the
TIPS procedure.
Figure 1 The patient's tumor markers over time since her breast cancer was diagnosed.
Figure 2 Splenomegly, ascites and normal appearing hepatic pa-
renchyma.Fournier et al. Journal of Medical Case Reports 2010, 4:112
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Meanwhile, histopathology revealed the true nature
and cause for our patient's symptoms and portal hyper-
tension. Biopsy revealed the unusual pattern of
micronodular cirrhosis induced by a diffuse intrasinusoi-
dal infiltration of moderately-differentiated breast cancer
cells. The cells biopsied were HER-2/neu negative, with
estrogen receptor (ER) at 7% and progesterone receptor
(PR) at 3%. The original tumor prior to any therapy was
marked with an ER of 69%, PR of 27%, and negative HER-
2/neu negative. Metastatic breast carcinoma cells with
distinct ductal histoarchitecture were diffusely infiltrat-
ing our patient's liver sinusoids (Figures 4, 5, 6, 7), which
was similar to the cases presented by Allison et al. [1].
Our patient's ascitic fluid contained morphologically
similar tumor cells. She continued a rapid downhill
course with her total bilirubin increasing to 17 mg/dl. A
last effort using the administration of infusional cisplati-
num (Cisplatin) 25 mg/m2/d for 5 days was associated
with a slight decrease in all her tumor markers, although
this lasted only for days. The patient and her family sub-
sequently requested hospice care. A graph showing our
patient's tumor markers since she was diagnosed with
breast cancer, along with the dates she began different
treatments, is shown in Figure 1.
Figure 4 200× magnification of photomicrograph of liver paren-
chyma showing micronodular cirrhotic changes and extensive in-
filtration by metastatic breast cancer cells.
Figure 5 630× magnification of photomicrograph showing meta-
static breast carcinoma cells with distinct ductal histoarchitec-
ture infiltrating liver sinusoids (arrows).
Figure 6 630× magnification of photomicrograph showing meta-
static breast carcinoma cells infiltrating the liver sinusoids. Note 
the duct-like structures (arrows) with lining cells that have lost nuclear 
polarity and the mitotic form (dashed arrow).
Figure 3 Splenomegly, ascites, esophageal varacies and normal 
appearing hepatic parenchyma.Fournier et al. Journal of Medical Case Reports 2010, 4:112
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Discussion
Our patient demonstrates two important and unique fea-
tures involving the treatment and histopathology of
breast cancer metastases. The fact that she was able to
enjoy an additional six months of capecitabine (Xeloda)
control of painful bone metastases was due to a change in
dosing schedule, the biological basis of which was pro-
vided by the Norton-Simon model. This model, which
was based on Gompertzian tumor growth, suggests that
by increasing the dose density of chemotherapy during
the rapid tumor growth phase, greater cell kill can be
i nduc ed.  Enha nc ed c e l l ki ll is t h us  o btai ned t hr o ugh a
greater chemotherapy dose rate. Such a strategy ideally
limits the regrowth of tumor cells between cycles of che-
motherapy [2-5].
The pioneering work by Norton et al. on capecitabine
(Xeloda) scheduling motivated the schedule change for
our patient [2-6]. The biweekly 7/7 capecitabine schedule
delivered 28,000 mg of capecitabine over 14 days com-
pared to the FDA-approved 14/7 protocol that delivered
35000 mg over 14 days every 21 days. One difference is
that 28000 mg of capecitabine delivered in the 7/7 sched-
ule was ingested over 7 days (dose density = 28000 mg/
7d) while the 35000 mg dose of the 14/7 schedule was
delivered over 14 days (dose density = 17500 mg/7d).
Compared to the 14/7 schedule the 7/7 biweekly schedule
delivered 1.6 times the dose of capecitabine over the 7-
day period of drug administration. The 14/7 schedule was
the maximum tolerable dose for our patient because of
her gastrointestinal toxicity, while the 7/7 schedule had
no such toxicity. This benefit was as predicted by the
experiments outlined in Norton's work [6].
The second feature is of occult liver metastases due to
breast cancer. Most liver metastases from breast cancer
are apparent on contrast-enhanced CT imaging and
rarely cause portal hypertension and progressive liver
failure. Allison et al. described three cases of breast can-
cer metastatic to the liver in the absence of CT detection
[1]. The livers in their patients were homogeneous and
c o n t a i n e d  n o  d i s c r e t e  m e t a s t a t i c  l e s i o n s .  O n l y  o n e  o f
their patients had portal hypertension by hepatic ultra-
sound. Microscopically, as noted in our patient, there
were moderately-differentiated tumor cells diffusely infil-
trating throughout the hepatic sinusoids [1]. Allison et al.
concluded that intrasinusoidal hepatic metastases of
breast carcinoma can occupy a large percentage of the
hepatic volume, yet remain occult both radiographically
and macroscopically. Their patients presented with
advanced liver failure. They mentioned additional breast
cancer patients presenting with diffuse intrasinusoidal
hepatic metastases (all invasive ductal subtypes) as a
result of their review of the English literature where 9 of
18 had no radiological evidence of metastatic disease [1].
There is a previously described radiological entity
termed "pseudo-cirrhosis" due to breast metastases
treated with chemotherapy [7,8]. This entity is the result
of a reaction to chemotherapy of visible hepatic metasta-
ses which results in the radiological appearance of
macronodular cirrhosis. Our case is unique because of
the unusual pattern of tumor cell infiltration and the
peculiar micronodular cirrhotic response that remained
radiographically occult within our patient's liver paren-
chyma while causing radiologically advanced changes of
portal hypertension including splenomegaly, esophageal
varacies, ascites and thrombocytopenia (the etiology of
which was initially confused with bone marrow infiltra-
tion by tumor and or chemotherapy effect).
Conclusion
This case report presents evidence for the superiority of a
7/7 day capecitabine [Xeloda] dosing schedule. This is the
first clinical demonstration of the 7/7 regimen's superior-
ity where the patient acted as her own control. The supe-
riority of the 7/7 regimen was predicted in the work of
Norton et al. based on the Norton-Simon hypothesis and
on animal studies where the maximal affect of capecit-
abine occurs about 8 days after the initiation of therapy.
Drug delivered after that period (days 8 to 14) had a
higher toxicity-to-benefit ratio [6].
Medical oncologists depend extensively on the use of
contrast-enhanced CT imaging to rule out hepatic metas-
tases. Although isodense tumor metastases are well
described, their presentation as portal hypertension with
rapid progressive liver failure is unusual. Patients with
breast cancer who suddenly develop signs and symptoms
of portal hypertension in the absence of contrast-
enhanced CT imaging, hepatic abnormalities will require
biopsy to rule out liver metastases.
Figure 7 630× magnification of photomicrograph showing the 
results of immunohistochemical staining for the estrogen recep-
tor. Note the metastatic, estrogen receptor positive breast carcinoma 
cells infiltrating the liver sinusoids (arrow).Fournier et al. Journal of Medical Case Reports 2010, 4:112
http://www.jmedicalcasereports.com/content/4/1/112
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